779-72-6

Upstream product

• 146328-85-0 5-bromo-2-fluoro-benzoic acid 
• 57381-59-6 methyl 2-fluoro-5-bromobenzoate 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 327-95-7 4-fluorobenzene-1,3-dioic acid 

Downstream Products

• 816449-69-1 4-fluoro-3-hydroxymethyl-benzoic acid methyl ester 
• 816449-70-4 methyl 2-fluoro-5-(hydroxymethyl)benzoate 

Relevant academic research and scientific papers

TRICYCLIC COMPOUND AS CRTH2 INHIBITOR

Provided are a tricyclic compound as shown in formula (I) as a CRTH2 inhibitor, or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a solvate thereof, and the use thereof in treating diseases related to CRTH2 receptors.

INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

Indole derivatives with CRTH2 inhibitor activity

The invention discloses indole derivatives having CRTH2 inhibitor activity and shown as formula (I) in the description or pharmaceutically acceptable salts of the indole derivatives and an applicationof the indole derivatives to treatment of CRTH2 recepto

TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.